This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): 3M-051
Description: 3M-051 is a toll-like recepter 7/8 (TLR7/8) agonist.
3M and Ascend
In December 2013, Ascend entered into an agreement with 3M to evaluate 3M-051 in combination with Ascend's proprietary cancer vaccine technology. Under the terms of the agreement, 3M will provide access to the proprietary TLR7/8 agonist 3M-051 that will be chemically conjugated to Ascends ASN platform. Both companies will contribute to the collaboration with 3M providing good laboratory practices (GLP) and good manufacturing practices (GMP) material for preclinical and clinical studies. These preclinical studies will last up to 12 months. No further terms have been disclosed.
Partners: Ascend Biopharmaceuticals Ltd.
Additional information available to subscribers only: